Autolus Therapeutics AUTL Stock
Autolus Therapeutics Price Chart
Autolus Therapeutics AUTL Financial and Trading Overview
| Autolus Therapeutics stock price | 1.33 USD |
| Previous Close | 2.89 USD |
| Open | 2.86 USD |
| Bid | 2.77 USD x 800 |
| Ask | 2.95 USD x 900 |
| Day's Range | 2.82 - 2.92 USD |
| 52 Week Range | 1.6 - 3.79 USD |
| Volume | 346.57K USD |
| Avg. Volume | 675.63K USD |
| Market Cap | 489.8M USD |
| Beta (5Y Monthly) | 1.548476 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.31 USD |
AUTL Valuation Measures
| Enterprise Value | 184.47M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3690476 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 65.42911 |
| Price/Book (mrq) | 1.8352787 |
| Enterprise Value/Revenue | 24.643 |
| Enterprise Value/EBITDA | -1.168 |
Trading Information
Autolus Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.548476 |
| 52-Week Change | 27.47% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.79 USD |
| 52 Week Low | 1.6 USD |
| 50-Day Moving Average | 2.34 USD |
| 200-Day Moving Average | 2.31 USD |
AUTL Share Statistics
| Avg. Volume (3 month) | 675.63K USD |
| Avg. Daily Volume (10-Days) | 664.63K USD |
| Shares Outstanding | 173.08M |
| Float | 67.66M |
| Short Ratio | 1.58 |
| % Held by Insiders | 8.44% |
| % Held by Institutions | 76.89% |
| Shares Short | 1.61M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2205.22% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.044% |
| Return on Equity (ttm) | -56.34% |
Income Statement
| Revenue (ttm) | 7.49M USD |
| Revenue Per Share (ttm) | 0.07 USD |
| Quarterly Revenue Growth (yoy) | 678.30% |
| Gross Profit (ttm) | -130860000 USD |
| EBITDA | -157894000 USD |
| Net Income Avi to Common (ttm) | -151588000 USD |
| Diluted EPS (ttm) | -1.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 343.03M USD |
| Total Cash Per Share (mrq) | 1.98 USD |
| Total Debt (mrq) | 27.32M USD |
| Total Debt/Equity (mrq) | 10.23 USD |
| Current Ratio (mrq) | 9.937 |
| Book Value Per Share (mrq) | 1.542 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -119697000 USD |
| Levered Free Cash Flow (ttm) | -104842376 USD |
Profile of Autolus Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | The MediaWorks |
| ZIP | W12 7FP |
| Phone | 44 20 3829 6230 |
| Website | https://www.autolus.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 399 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Q&A For Autolus Therapeutics Stock
What is a current AUTL stock price?
Autolus Therapeutics AUTL stock price today per share is 1.33 USD.
How to purchase Autolus Therapeutics stock?
You can buy AUTL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Autolus Therapeutics?
The stock symbol or ticker of Autolus Therapeutics is AUTL.
Which industry does the Autolus Therapeutics company belong to?
The Autolus Therapeutics industry is Biotechnology.
How many shares does Autolus Therapeutics have in circulation?
The max supply of Autolus Therapeutics shares is 266.13M.
What is Autolus Therapeutics Price to Earnings Ratio (PE Ratio)?
Autolus Therapeutics PE Ratio is now.
What was Autolus Therapeutics earnings per share over the trailing 12 months (TTM)?
Autolus Therapeutics EPS is -0.86 USD over the trailing 12 months.
Which sector does the Autolus Therapeutics company belong to?
The Autolus Therapeutics sector is Healthcare.
Autolus Therapeutics AUTL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}